NIB-103

N/A

Report date: 2025/06/05 20:00:13

Base Information

Drug NameNIB-103
Drug Alias NameNIB-103TAK-103
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesYamaguchi UniversityNoile-Immune Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesYamaguchi UniversityTakara Bio IncNoile-Immune Biotech Inc
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A